Pomer krátenia spoločnosti Apellis Pharmaceuticals Inc

Aká je hodnota metriky Pomer krátenia spoločnosti Apellis Pharmaceuticals Inc?

Hodnota metriky Pomer krátenia spoločnosti Apellis Pharmaceuticals Inc je 5.06

Aká je definícia metriky Pomer krátenia?

Pomer krátenia (Short ratio) je pomer akcií predaných na krátko a priemerným denným objemom.

Short ratio is calculated by dividing the number of shares sold short by the average daily trading volume, generally over the last 30 trading days. The ratio represents the number of days it takes short sellers on average to repurchase all the borrowed shares. The ratio is used by both fundamental and technical traders to identify trends.

The percentage represents the number of days it takes short sellers on average to repurchase all the borrowed shares. Short selling is the practice of selling securities or other financial instruments that are not currently owned, and subsequently repurchasing them. In the event of an interim price decline, the short seller profits, since the cost of (re)purchase is less than the proceeds received upon the initial (short) sale. Conversely, the short position closes out at a loss if the price of a shorted instrument rises prior to repurchase. A high short ratio can be an indicator that there will be some buying pressure on the security that would increase its price.

Čomu sa venuje spoločnosť Apellis Pharmaceuticals Inc?

apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.

Firmy s metrikou pomer krátenia podobnou spoločnosti Apellis Pharmaceuticals Inc